NOV 02, 2016 6:00 AM PDT

Fast and easy identification of disease causing variants in hereditary diseases using patient phenotype information and testing for different modes of inheritance

Speaker
  • Associate Director Global Product Management NGS, QIAGEN
    Biography
      Dr. Anika Joecker is Associate Director Global Product Management NGS at QIAGEN. She joined CLC bio (now QIAGEN) in 2011 as Senior Bioinformatician/Project & Team Manager and worked since 2013 in product management at QIAGEN - first in Bioinformatics and recently now as product manager of the GeneReader NGS System. Anika Joecker holds a Ph.D. in Biology/Bioinformatics from University of Cologne, Germany, and has worked as Bioinformatics Group Leader at the German Cancer Research Center (Heidelberg, Germany).

    Abstract

    Whole genome and exome sequencing is being widely used to identify disease-causing variants in patients with hereditary and rare diseases. Discovering the true disease-causing variants often requires testing different modes of inheritance (de novo, compound heterozygote, recessive, or dominant). Indeed, selecting the most promising ones that best explain a patient’s entire phenotype, can be very time-consuming. In this presentation, we will present our new one-step trio workflow, which automatically checks for all modes of inheritance using optimized parameter settings for the complete data analysis, filtering, and interpretation workflow. We will illustrate this by reporting data from cases with undiagnosed genetic disorders. In combination with our new patient phenotype-driven sorting algorithm, which ranks variants using phenotype-disease associations, this simplifies and accelerates the identification of disease-causing variants. 


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    Loading Comments...
    Show Resources